New York, Jan 21, 2026, 19:34 EST — After-hours
Thermo Fisher Scientific Inc shares climbed 2.8%, closing at $636.30 on Wednesday and hitting a new 52-week high. After hours, the stock barely moved following heavy volume earlier in the day. The S&P 500 advanced 1.16%, while the Dow added 1.21%. (MarketWatch)
This move is significant as investors approach the upcoming quarterly reports with the stock already trading close to its peak. Traders will watch closely for any changes in biopharma spending and lab tool demand, the key drivers that typically push these shares up or down quickly.
Shares in other life-science tools firms climbed, with Danaher and Waters leading the charge as the sector caught a broad risk-on mood. That likely fueled the demand for Thermo Fisher despite no new company news on Wednesday. (MarketWatch)
The New York Stock Exchange filed a Form 25 with the SEC to delist Thermo Fisher’s 3.200% senior notes maturing in 2026. This move concerns the notes only, not Thermo Fisher’s common stock. (SEC)
Thermo Fisher has boosted its presence in biopharma and lab services through acquisitions, including a planned all-cash purchase of clinical trial data company Clario. The deal is expected to close by mid-2026, pending regulatory approvals. (Thermo Fisher Investors)
At this month’s J.P. Morgan Healthcare Conference, CEO Marc Casper highlighted a growing push to reshore drug manufacturing. Evercore ISI analyst Vijay Kumar called the mood optimistic but noted no raised expectations for 2026. “There’s a very big focus on reshoring more production and activity to the U.S.,” Casper said, adding, “So actually we see an improving set of end markets.” (Reuters)
However, the company warned of ongoing challenges, notably softer sales in China linked to a government program that purchases medical devices in bulk at deep discounts. In October, Thermo Fisher noted that acquisitions were cushioning this drop and raised its full-year outlook, citing strong demand for lab tools. (Reuters)
Shares have surged to a fresh high, but expectations are tightening. Any cautious guidance, a slip in orders, or hints that customers remain cautious with spending might flip Wednesday’s gains into losses just as fast.
Thermo Fisher is set to release its fourth-quarter and full-year 2025 earnings before the market opens on Thursday, Jan. 29. The company will follow up with a conference call at 8:30 a.m. ET. Investors are focused on guidance and updates regarding biopharma services demand and developments in China, which could drive the stock’s next move. (Thermo Fisher Investors)
